Histopathological study of erythropoietin protective effect on carbon monoxide-induced cardiotoxicity in rat

Document Type: Original Article


1 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University

2 Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University

3 Pharmaciutical Research Center, Institute of Neuropharmacology, Kerman University

4 Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Ahl Al Bayt, Karbala, Iraq

5 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

6 Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

7 Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

8 Immunobiochemistry Laboratory, Immunology Research Center, Bu-Ali research Institute, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

9 Department of Pathology, School of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

10 Electron Microscope Unit, Bu-Ali Research Institute, Mashhad University of Medical Science, Mashhad, Iran

11 School of Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran


Objective(s): Cardiotoxicity is one of the major consequences in carbon monoxide poisoning. Following our previous work, in this study we aimed to define the myocardium changes induced by carbon monoxide (CO) intoxication and evaluate erythropoietin (EPO) effect on CO cardiotoxicity in rat.
Materials and Methods:  Severe carbon monoxide toxicity induced by 3000 ppm CO in Wistar rat.  EPO was administrated (5000 IU/Kg, intraperitoneal injection) at the end of CO exposure and then the animals were re-oxygenated with the ambient air. Subsequently heart was removed and assessed by histopathology and electron microscopy examinations.
Results: 3000 ppm CO induced significant myocardium injury; multiple foci of necrosis and lymphocyte infiltration compare with the control (P˂0.05). Electron microscopy examination showed myofibril lysis and mitochondrial swelling in myocardium due to 3000 ppm CO poisoning.  However EPO administration after CO exposure resulted in significant reduction in cardiomyocytes injury (P˂0.05).
Conclusion: Our results represented protective effect of EPO on cardiac injury induced by CO intoxication in rat.


1. Guzman JA. Carbon monoxide poisoning. Crit Care Clin 2012;28:537-548.

2. Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med 2009;360:1217-1225.

3. Goldstein M. Carbon monoxide poisoning. J Emerg Nurs 2008; 34:538-542.

4. EJ L. Carbon monoxide poisoning. In: Shannon MW BS, Burns M, editor. Haddad and Winchester's clinical management of poisoning and drug overdose. 4st ed. Philadelphia: Saunders/Elsevier; 2007.p. 1297-1307.

5. Khadem-Rezaiyan M, Afshari R. Carbon monoxide poisoning in Northeast of Iran. J Forensic Leg Med 2016;41:1-4.

6. Nazari J, Dianat I, Stedmon A. Unintentional carbon monoxide poisoning in Northwest Iran: A 5-year study. J Forensic Leg Med 2010;17:388-391.

7. Garg J, Krishnamoorthy P, Palaniswamy C, Khera S, Ahmad H, Jain D, et al. Cardiovascular abnormalities in carbon monoxide poisoning. Am J Ther 2014  [Epub ahead of print].

8. Lippi G, Rastelli G, Meschi T, Borghi L, Cervellin G. Pathophysiology, clinics, diagnosis and treatment of heart involvement in carbon monoxide poisoning. Clin Biochem 2012;45:1278-1285.

9. Kalay N, Ozdogru I, Cetinkaya Y, Eryol NK, Dogan A, Gul I, et al. Cardiovascular effects of carbon monoxide poisoning. Am J Cardiol 2007;99:322-324.

10. Burnett RT, Dales RE, Brook JR, Raizenne ME, Krewski D. Association between ambient carbon monoxide levels and hospitalizations for congestive heart failure in the elderly in 10 Canadian cities. Epidemiology 1997;8:162-167.

11. Simkhovich BZ, Kleinman MT, Kloner RA. Air pollution and cardiovascular injury epidemiology, toxicology, and mechanisms. J Am Coll Cardiol 2008;52:719-26.

12. Lombardero M, Kovacs K, Scheithauer BW. Erythropoietin: a hormone with multiple functions. Pathobiology 2011;78:41-53.

13. Paschos N, Lykissas MG, Beris AE. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci 2008;4:161-168.

14. Erik Li, Regien GS, Peter van der M, Adriaan AV, Dirk JvV, Wiek HvG. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.

15. Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 2005;19:439-446.

16. Mastromarino V, Musumeci MB, Conti E, Tocci G, Volpe M. Erythropoietin in cardiac disease: effective or harmful? J Cardiovasc Med (Hagerstown) 2013;14:870-878.

17. Gao D, Ning N, Niu X, Dang Y, Dong X, Wei J, et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J 2012;164:715-727.

18. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-291.

19. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005;100:397-403.

20. Mastromarino V, Volpe M, Musumeci MB, Autore C, Conti E. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond) 2011;120:51-63.

21. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sciences 2006;78:2255-2264.

22. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005;19:1323-1325.

23. Asgharian Rezaee M, Moallem SA, Imenshahidi M, Farzadnia M, Mohammadpour AH. Effects of erythropoietin on electrocardiogram changes in carbon monoxide poisoning: an experimental study in rats. Iran J Pharm Res 2012;11:1191-1199.

24. Iheagwara KN, Thom SR, Deutschman CS, Levy RJ. Myocardial cytochrome oxidase activity is decreased following carbon monoxide exposure. Biochim Biophys Acta 2007;1772:1112-1116.

25. Favory R, Lancel S, Tissier S, Mathieu D, Decoster B, Neviere R. Myocardial dysfunction and potential cardiac hypoxia in rats induced by carbon monoxide inhalation. Am J Respir Crit Care Med 2006;174:320-325.

26. Dragelyte G, Plenta J, Chmieliauskas S, Jasulaitis A, Raudys R, Jovaisa T, et al. Myocardial Rupture following Carbon Monoxide Poisoning. Case Rep Crit Care 2014;2014 [Epub ahead of print].

27. Jung YS, Lee JS, Min YG, Park JS, Jeon WC, Park EJ, et al. Carbon monoxide-induced cardiomyopathy. Circ J 2014;78:1437-1444.

28. Fineschi V, Agricola E, Baroldi G, Bruni G, Cerretani D, Mondillo S, et al. Myocardial findings in fatal carbon monoxide poisoning: a human and experimental morphometric study. Int J Legal Med 2000;113:276-282.

29. Mohamadpour AH, Moallem SA, Hashemzaei M, Abnous K, Tabatabaee Yazdi SA, Imenshahidi M. Effects of granulocyte colony-stimulating factor on electrocardiogram changes after carbon monoxide poisoning in rats. Drug Chem Toxicol. 2012; 35:353-60. Effects of granulocyte colony-stimulating factor on electrocardiogram changes after carbon monoxide poisoning in rats. Drug Chem Toxicol 2012;35:353-60.

30. Vogiatzi G, Briasoulis A, Tousoulis D, Papageorgiou N, Stefanadis C. Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther 2009;10:251-64.

31. Santhanam AVR, d'Uscio LV, Katusic ZS, Paul MV. Cardiovascular Effects of Erythropoietin: An Update. Adv Pharmacol 2010; 60:257-85.

32. Ammar HI, Saba S, Ammar RI, Elsayed LA, Ghaly WB, Dhingra S. Erythropoietin protects against doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2011;301:H2413-21.

33. Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S, et al. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther 2007;21:367-74.